Company / Cash & Equivalents
iSpecimen Inc. Cash & Equivalents History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.9M
FY2024
5-year range
$1.9M / $27.7M
FY2021-FY2024
Trend
-19.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $28M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2024 with a 3-year CAGR of -59.2%.
Declined from $28M to $2M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -59.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -59.2%, indicating a declining trend.
- In FY2024, cash & equivalents decreased 19.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.90 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.9M | -19.9% |
| FY2023 | $2.3M | -91.6% |
| FY2022 | $27.7M | +0.0% |
| FY2021 | $27.7M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026